AT1 receptor antagonist Candesartan in selected cirrhotic patients: effect on portal pressure and liver fibrosis markers.
J Hepatol
; 46(6): 1026-33, 2007 Jun.
Article
en En
| MEDLINE
| ID: mdl-17336417
ABSTRACT
BACKGROUND/AIMS:
The renin-angiotensin system plays an important role in hepatic fibrogenesis and in portal hypertension. To examine the long-term effects of Candesartan cilexetil, an angiotensin type 1 (AT1) receptor blocker, on portal-systemic haemodynamics and on liver fibrosis.METHODS:
Forty-seven compensated Child A and Child B (8) cirrhotic patients were randomly assigned to receive Candesartan cilexetil, 8 mg/d (N.24) and no treatment (N.23) for 1 year. Portal-systemic haemodynamic parameters, serological levels of procollagen (PIIINP), hyaluronic acid (HA) and transforming growth factor beta 1 (TGFbeta1) were assessed at baseline and after 12 months.RESULTS:
No patients discontinued or decreased the drug. The hepatic venous pressure gradient (HVPG) decreased significantly in treated patients (-8.4%+/-2.4) with a reduction >20% in 25% of cases vs+5.6%+/-2.9 in the untreated group. HA plasma levels decreased significantly in Candesartan treated patients in whom HVPG diminished and rose in untreated patients in whom HVPG increased.CONCLUSIONS:
In selected cirrhotic patients, pharmacological inhibition of the AT1 receptor is well tolerated and induced a mild reduction of portal pressure. This haemodynamic effect might be related to liver fibrogenesis activity.
Buscar en Google
Base de datos:
MEDLINE
Asunto principal:
Tetrazoles
/
Bencimidazoles
/
Compuestos de Bifenilo
/
Fibrosis
/
Receptor de Angiotensina Tipo 1
/
Bloqueadores del Receptor Tipo 1 de Angiotensina II
Tipo de estudio:
Clinical_trials
Idioma:
En
Revista:
J Hepatol
Asunto de la revista:
GASTROENTEROLOGIA
Año:
2007
Tipo del documento:
Article